Following is the schedule of Emerging Science abstracts to be presented at the 2013 AAN Annual Meeting. Abstracts qualify for Emerging Science presentations by having key aspects of research conducted after the October 15th abstract submission deadline and must be new and of sufficient scientific importance to warrant expedited presentation and publication.
The Science Committee is committed to presenting the best neuroscientific research at the Annual Meeting so we are excited to announce that we are accepting 12 abstracts for dual presentation this year and nine abstracts as poster presentations. The 12 dual presentation abstracts will be featured in data blitz format during the first 40 minutes of the Emerging Science Platform session from 5:45 p.m. to 6:25 p.m., followed by poster presentations in the same room from 6:25 p.m. to 7:00 p.m. The nine poster presentation abstracts will be included in Poster Session 4 on Wednesday, March 20 from 7:30 am to 12:00 pm.
001– “Novel CSF biomarkers for frontotemporal lobar degeneration with lesions immunoreactive to TDP–43 (FTLD–TDP)”– William T. Hu, Atlanta, GA
002– “Safety and efficacy of ORM–12741 on cognitive and behavioral symptoms in patients with Alzheimer’s disease: A randomized, double–blind, placebo–controlled, parallel group, multicenter, proof–of–concept 12 week study”– Juha Rouru, Turku, Finland
003– “CSF (1,3) b–D–glucan as an adjunctive test for invasive CNS fungal infection due to presumed Exserohilum rostratum”– Jennifer Lyons, Baltimore, MD
004– “Antipsychotic efficacy and motor tolerability in a Phase III placebo–controlled study of pimavanserin in patients with Parkinson’s disease psychosis (ACP–103–020)” – Jeffrey L. Cummings, Las Vegas, NV
005– “A phase 2, placebo–controlled, randomized, double–blind trial of tozadenant (SYN–115) in patients with Parkinson’s disease with wearing–off fluctuations on levodopa”– C. Warren Olanow, New York, NY
006– “A placebo controlled, randomized, double–blind study to assess the safety and clinical benefit of rasagiline as an add–on therapy to dopamine agonist monotherapy in early Parkinson’s disease (PD): The ANDANTE study”– Robert A. Hauser, Tampa, FL
007– “Davunetide for progressive supranuclear palsy: results of the AL–108–231, phase 2/3, 52 week, multi–center, randomized, double–blind, placebo–controlled clinical trial”– Adam L. Boxer, San Francisco, CA
008– “Interim analysis of 12 patients with amyotrophic lateral sclerosis (ALS) treated with autologous differentiated mesenchymal stem cells: Preliminary data of a Phase I/II clinical trial” – Dimitrios Karussis, Jerusalem, Israel
009– “A Study to Evaluate Efficacy, Safety and Tolerability of Single Doses of Tirasemtiv in Patients with Myasthenia Gravis”– Donald B. Sanders, Durham, NC
010– “Droxidopa Treatment Impact on Orthostatic Symptoms and Standing Systolic Blood Pressure in Patients with Parkinson’s Disease (PD) and Symptomatic Neurogenic Orthostatic Hypotension (NOH)”– Stuart H. Isaacson, Boca Raton, FL
011– “IMS–III Like Subgroup Analysis in the North American SOLITAIRE Stent–Retriever Acute Stroke Registry” – Osama O. Zaidat, Milwaukee, WI
012– “Mutations in DEPDC5 cause Familial Focal Epilepsy with Variable Foci and are a common cause of familial non–lesional focal epilepsy” – Massimo Pandolfo, Brussels, Belgium
P04.265– “A Multicentre, Randomised, Open–Label, Comparative Phase 4 Trial to Assess Changes in Dementia Diagnostic Category and Diagnostic Confidence after DaTscan Imaging in Subjects with an Uncertain Diagnosis of Dementia with Lewy Bodies (Possible DLB)” – Zuzana Walker, Essex, England
P04.266– “Neocortical ictal high frequency oscillations (HFO) are a surrogate marker of increased action potential firing rate and synchrony that discriminate the ictal focus from the penumbra.” – Shennan Weiss, New York, NY
P04.267– “Reduced ?5–ADIOL in CSF and Plasma as a Biomarker of Neurocognitive Impairment in HIV Infection” – Kaoru Saijo, La Jolla, CA
P04.268– “The role of stabilized neuropeptides derived from hyperimmune caprine sera (HICS) in motor neuron disease – implications for a novel therapeutic strategy” – Syed B. Haq, London, England
P04.269– “1H MRS Reveals Decreased Motor Cortex Glutathione in Patients with ALS” – Nora Weiduschat, New York, NY
P04.270– “Evidence of primary vascular injury after acute head trauma in the Traumatic Head Injury Neuroimaging Classification (THINC) Study” – Gunjan Parikh, Baltimore, MD
P04.271– “Natalizumab–associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis patients: survival and functional outcome when asymptomatic at diagnosis” – Tuan Dong–Si, Boston, MA
P04.272– “Pilot study of monthly pulse adrenocorticotropic hormone (ACTH) or methylprednisolone as an add–on therapy to beta–interferons for long–term treatment of multiple sclerosis” – Regina Berkovich, Valley Village, CA
P04.273– “Percutaneous Transluminal Venous Angioplasty (PTVA) is Ineffective in Correcting Chronic Cerebrospinal Venous Insufficiency (CCSVI) and May Increase Multiple Sclerosis (MS) Disease Activity in the Short Term: Safety and Efficacy Results of the 6–Month, Double–Blinded, Sham–Controlled, Prospective, Randomized Endovascular Therapy in MS (PREMiSe) trial” – Robert Zivadinov, Buffalo, NY
Disclaimer: The opinions expressed in this posting are those of the author only and do not represent the views of the American Academy of Neurology or any of its affiliated subsidiaries.
Please login to view and submit comments.